Key Takeaways
- Revenue down, gross profit up: Revenue declined 6% YoY on lower API and formulation prices, but gross profit rose 7% as price stabilization began to unlock margins.
- Greenfield drags are turning a corner: Tarapur teething issues are resolved and Sayakha trial production starts in February, setting up operating leverage that management expects will lift EBITDA margins toward 13-14% in FY26.
- US FDA approval opens a new export channel: The Tarapur API plant can now ship to the US, a market management says could contribute ₹70-80 Cr per annum at healthy margins, though meaningful revenue is a FY27 story.
- A self-inflicted process wound is now closed: The chlorosulfonation line's failed continuous process caused nine months of losses; rolling back to the old process curtails those losses immediately and margin recovery begins in Q4.
- What to watch next quarter: Whether Sayakha trial production converts to booked sales in Q1 FY26, the pace of gross margin unlocking now that input prices have stabilized, and any volume traction from the salicylic acid greenfield project.
Revenue & Margin Bridge
- Topline pressure was price-led, not volume-led: The 6% YoY revenue decline came from reduced market prices in the Formulation and Antibiotic API segments; on a YoY basis, the average price decline was only 2-2.5% in the December quarter.
- Gross margin unlocked despite the revenue drop: Because the company carries 90-100 days of inventory and uses FIFO accounting, falling raw material and selling prices had compressed margins in prior quarters; now that prices have stabilized, that headwind reverses and gross profit rose 7% YoY.
- Other expenses spiked on one-offs: The quarter carried roughly ₹1 Cr of doubtful debts, plus CPHI trade fair costs and Diwali-related expenses, all nonrecurring and together making other expenses look elevated.
- Specialty segment improved QoQ but carries a scar: The improvement was driven by campaign-based old products; the chlorosulfonation line expansion, meant to run at 300-400 tons per month, never crossed 40-50 tons because a new continuous process caused quality issues and low market acceptability, generating losses for nine months before management rolled it back to the old process.
- The rollback limits further damage: The line is now operational at 100 tons per month on the old process; scaling back to original planned capacity will take 3-4 months, but losses have already been curtailed and a slight gross margin improvement is expected from the March quarter onward.
Adhish Patil: "So that is the reason why we have taken a call to roll back that process to the old one where, in fact, last 9 months, we have been suffering losses because of the quality issues for that chlorosulfonation -- the newer chlorosulfonation line, which has been rolled back. And now all those losses have been already curtailed."
Greenfield Projects: The Margin Path
- Tarapur greenfield is past its teething phase: Issues that had constrained output are now sorted; management expects to ramp production to 500-plus tons per month by end of March 2025, with a sequential capacity ramp reaching 1,600 metric tons per month by end of FY26.
- Sayakha is the next catalyst: The greenfield Specialty Chemicals project in Gujarat (backward integration) has all necessary permissions and raw materials procured; trial production begins in February, with sales from those products visible in Q1 FY26 financials.
- Salicylic acid project has been a margin drag: Started in FY25, this greenfield project caused a measurable EBITDA-level drag this quarter; as utilization improves, operating leverage is expected to kick in and help lift consolidated margins.
- Under-absorption in certain antibiotic products: Some products where market share was scaled up are not yet running the most efficient process at plant scale; R&D is complete and small brownfield capex or modifications are planned to improve the gross contribution profile.
- The long-term margin bet: Management's base case, assuming the current environment holds, is that backward integration from Sayakha plus higher utilization of the salicylic acid project should push EBITDA margins toward 15% over the next 2-3 years.
Adhish Patil: "We can say that if the situation what is there now, if it remains like that for next 2 to 3 years, we should definitely start inching towards 15% EBITDA margins, frankly speaking."
US FDA & Export Opportunity
- The approval unlocks a new revenue stream: Aarti Drugs received an Establishment Inspection Report (EIR) for its Tarapur API facility, clearing it to export Ciprofloxacin HCL, Zolpidem Tartrate, Raloxifene HCL, Celecoxib, and Niacin to the US market.
- Revenue potential is meaningful but back-end loaded: Management estimates the plant's full potential at ₹70-80 Cr per annum, with the possibility of doubling that if two more production plants are added; however, European markets will open first, and meaningful US contribution is not expected in FY26, likely flowing only from FY27.
- Margins could stay in the late 30s: When challenged on whether 30%+ EBITDA margins are still achievable given increased competition, management argued it is "quite possible" because very few API facilities manufacture for the US FDA, and the key is running year-round production without changeovers that erode margins.
- Formulation plant also cleared: UK MHRA and US FDA approvals were received for the formulation plant, and a brownfield expansion adding roughly 30% capacity has been completed; revenues from that added capacity start kicking in from Q1 FY26.
Adhish Patil: "When it comes to API manufacturing facilities for US FDA, so there are very limited facilities which manufacture APIs for US FDA. In Formulation, it might be slightly different, but in API space -- and the main trick is to manufacture that product year-round. Means if there are more changeovers in the plant, obviously, the EBITDA margins get a hit because of changeover."
Segment & Product Dynamics
- Antibiotic API prices were the main drag: Ofloxacin saw price declines steeper than other products, though some products in the portfolio had positive price movement; metformin prices are now very stable with no change.
- Formulation segment is a near-term mixed story: The next quarter is expected to be flattish, but over the next two quarters a strong order book supports good growth, especially in exports; FY26 looks stronger as the 30% brownfield capacity addition, new products, and a shift from domestic CMO to international markets drive a considerable EBITDA improvement.
- Antidiabetic portfolio is building slowly: Pioglitazone and teneligliptin are contributing; vildagliptin has had commercial batches taken but is not yet a meaningful contributor.
- Oncology pipeline is 15-24 months out: Five products (dasatinib, lenalidomide, abiraterone among them) have been filed or will be filed very soon in the US and Europe; the antidiabetic pipeline adds another 6-7 products in the DPP-4 inhibitor and SGLT2 categories over the same horizon.
- Dermatology derivatives are ready but demand-dependent: The company has a few derivatives ready; whether it manufactures them for cosmetic and skin applications depends on how quickly sales of the base dermatology product pick up.
Volume & Value Growth Outlook
- Volume growth is the explicit target: Management committed to trying for 15-20% volume growth, with salicylic acid as a key driver; per an analyst's math, combining that volume growth with a 2-3% negative rate variance yields roughly 15% value growth with much better margins, a calculation management confirmed as correct.
- Price outlook is cautiously stable: Management does not expect further price declines; if crude rises due to Russian sanctions, API prices could even see an upward trajectory; if crude stays stable, the gross margin unlocking from stabilized input costs should play out over coming quarters.
- The ₹4,000 Cr topline ambition remains alive: Management reiterated that roughly ₹4,000 Cr of consolidated revenue is still achievable in three years' time.
Adhish Patil: "Yes. So volume growth, we will definitely try for 15% to 20%, no doubt about that. We'll try to -- with the help of salicylic acid, I hope we'll get to those numbers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Tarapur greenfield ramp-up | Production of 500-plus tons per month | By end of March 2025 |
| Sequential capacity ramp | 1,600 metric tons per month | By end of FY26 |
| Sayakha trial production | Trial production to commence | February 2025 |
| Sayakha revenue visibility | Sales from greenfield products visible in financials | Q1 FY26 |
| Formulation capex completion | Facility update completed | End of FY25 |
| Formulation brownfield capacity contribution | Revenues from 30% additional capacity start kicking in | Q1 FY26 |
| Chlorosulfonation margin improvement | Slight gross margin improvement begins | March quarter (Q4 FY25) |
| Chlorosulfonation capacity restoration | Scale back to original planned levels with old process | 3-4 months |
| US FDA plant meaningful revenue contribution | Material revenue from US market | FY27 (not FY26) |
| Solar plant operation | Commence operation | End of H1 FY26 |
| FY26 EBITDA margin target | 13-14% EBITDA margins | FY26 |
| Long-term EBITDA margin trajectory | Inching toward 15% | 2-3 years, assuming current conditions hold |
| Consolidated revenue ambition | Roughly ₹4,000 Cr | In 3 years' time |
| Volume growth target | 15-20% volume growth | Next year (FY26) |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹568 cr, decline of 6% YoY from ₹607 cr |
| Gross profit | ₹207 cr, up 7% YoY from ₹202 cr |
| Formulation revenue | ₹48.6 cr, with 47% from exports |
| API price variance (YoY) | -2% to -2.5% on an average basis |
| API price variance (sequential, FY25) | -5% to -7% price drop over the financial year |
| EBITDA margin guidance (FY26) | 13% to 14% |
| EBITDA margin aspiration (2-3 years) | ~15% if current conditions persist |
| Revenue aspiration (3 years) | ~₹4,000 cr on a consolidated basis |
| Volume growth target (FY26) | 15% to 20% |
| Capex incurred (9M FY25) | ₹136 cr |
| Capex guidance (FY25 full year) | ~₹200 cr |
| Tarapur greenfield production ramp-up target | 500-plus tons per month by end of March 2025 |
| Total capacity ramp-up target | 1,600 metric tons per month by end of FY26 |
| Antidiabetic segment revenue share (standalone) | 12% to 13% |
| US FDA plant revenue potential (current) | ₹70 cr to ₹80 cr per annum |